Regeneron Pharmaceuticals (REGN) said Thursday it won $135.6 million dollars in compensatory damages and $271.2 million in punitive damages in its antitrust case against Amgen (AMGN).
A jury in the U.S. District Court for the District of Delaware found Amgen using cross-therapeutic bundled rebates to block Regeneron's cholesterol drug Praluent from competing in the market, Regeneron said in a statement.
Amgen allegedly leveraged its anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select its Repatha as the exclusive cholesterol treatment over Praluent, the company said.
"Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent," the company said in the statement.
Amgen didn't immediately respond to a request for comment from MT Newswires.
Regeneron shares rose 2.4% in regular trading Thursday, and Amgen gained 3.6%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。